Hosted on MSN8h
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
Merck MRK announced that EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting conditional ...
Zacks.com on MSN7h
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) ...
PharmaTimes14h
CSL receives positive opinion for garadacimab in hereditary angioedema
Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
emjreviews.com11h
Lilly gains EU backing for drug to treat Crohn’s disease
The drug has received a nod from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the ...
Pharmabiz16h
EMA’s CHMP committee recommends approval of Biocon Biologics’ Yesintek
EMA’s CHMP committee recommends approval of Biocon Biologics’ Yesintek: Our Bureau, Bengaluru Monday, December 16, 2024, 14:30 Hrs [IST] Biocon Biologics (BBL), a fully integr ...
Daily1d
Gilead Sciences Seladelpar gets positive CHMP opinion for Primary Biliary Cholangitis
Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for ...
Pharmabiz18h
EMA’s human medicine committee recommends marketing approval for acoramidis for treatment of transthyretin amyloid cardiomyopathy
EMA’s human medicine committee recommends marketing approval for acoramidis for treatment of transthyretin amyloid cardiomyopathy: Berlin Monday, December 16, 2024, 13:00 Hrs [I ...